190A — Chordia Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- ¥11bn
- ¥8bn
- ¥3bn
Annual cashflow statement for Chordia Therapeutics, fiscal year end - August 31st, JPY millions except per share, conversion factor applied.
2022 August 31st | 2023 August 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | JAS | JAS |
| Status: | Final | Final |
| Net Income/Starting Line | -1,777 | 226 |
| Depreciation | ||
| Non-Cash Items | -16.4 | -15.8 |
| Other Non-Cash Items | ||
| Changes in Working Capital | 85.8 | 328 |
| Change in Prepaid Expenses | ||
| Change in Other Assets | ||
| Change in Accounts Payable | ||
| Other Operating Cash Flow | ||
| Cash from Operating Activities | -1,704 | 544 |
| Capital Expenditures | -13.5 | -0.723 |
| Purchase of Fixed Assets | ||
| Purchase / Acquisition of Intangibles | ||
| Other Investing Cash Flow Items | -1.15 | 1.07 |
| Other Investing Cash Flow | ||
| Cash from Investing Activities | -14.7 | 0.345 |
| Net Issuance / Retirement of Stock | ||
| Cash from Financing Activities | 3,976 | 0 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 2,257 | 544 |